Balanced news tone
News Sentiment
ANIP sentiment intelligence
ANI Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
45 relevant articles
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-4.6% over one week, +0.5% over four weeks, trend active, and near fair-value range.
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
80/100 classification
One-week reaction
-4.6%
Price reacting lower
Trend fit
Trend active
0.5% over four weeks
Fair value
21.2%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
26
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
ANI Pharmaceuticals (ANIP) announced its intent to appeal rulings in the CG Oncology matter to the Delaware Supreme Court after a trial court denied its motions for a new trial and judgment. The company aims to recover the value of assets sold to CG Oncology in 2010, specifically
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 17 Jul 2026 02:10
- Source
- Market source
Investing.com Canada
Direct company coverage
ANI Pharmaceuticals plans appeal after trial court ruling By Investing.com
ANI Pharmaceuticals announced its intent to appeal a Delaware trial court's denial of its post-trial motions in a dispute with CG Oncology. The company is seeking to recover the value of assets sold in 2010 and a 5% running royalty on future sales of cretostimogene grenadenorepve
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 02:05
- Source
- Investing.com Canada
MT Newswires
Direct company coverage
ANI Pharmaceuticals Plans to Appeal Trial Court Rulings in CG Oncology Case
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 21:19
- Source
- MT Newswires
AOL.com
Direct company coverage
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 19:39
- Source
- AOL.com
MLQ.ai
Direct company coverage
Frontier tech research, news & data
This article analyzes the growth of ANI Pharmaceuticals Inc. (ANIP), focusing on its revenue, net income, and EPS growth rates year-over-year. It provides a detailed breakdown of these financial metrics on both an annual and quarterly (trailing-twelve-month) basis, highlighting s
- Tone
- Positive 81/100
- Event
- Earnings
- Published
- 15 Jul 2026 04:45
- Source
- MLQ.ai
GuruFocus
Direct company coverage
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP)
Meredith Cook, Senior Vice President at ANI Pharmaceuticals Inc (ANIP), sold 500 shares of the company on July 13, 2026. This transaction continues a trend of insider selling over the past year, with no insider buys recorded against 52 insider sells. The stock is currently priced
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 14 Jul 2026 22:41
- Source
- GuruFocus
Stock Titan
Direct company coverage
ANI Pharmaceuticals (ANIP) counsel sells 500 shares under 10b5-1 plan
ANI Pharmaceuticals' Senior Vice President, General Counsel, and Secretary, Meredith Cook, sold 500 shares of common stock at $81.84 per share on July 13, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established in September 2025. Following the sale, Cook
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 14 Jul 2026 19:41
- Source
- Stock Titan
Sahm
Direct company coverage
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
ANI Pharmaceuticals announced positive six-month topline data from its Phase 4 SYNCHRONICITY clinical trial evaluating Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis (NIU-PS). The trial met both co-primary endpoints, showing statistica
- Tone
- Positive 94/100
- Event
- Market update
- Published
- 14 Jul 2026 02:10
- Source
- Sahm
Proactive financial news
Direct company coverage
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced positive topline results from its Phase 4 SYNCHRONICITY trial for a fluocinolone acetonide intravitreal implant used to treat chronic non-infectious uveitis. The study successfully met both primary endpoints, showing improved vision
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 13 Jul 2026 13:41
- Source
- Proactive financial news
Stock Titan
Direct company coverage
Eye implant trial from ANI Pharmaceuticals improves vision and retinal thickness at 6 months
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 10:50
- Source
- Stock Titan
Investing.com
Direct company coverage
ANI Pharmaceuticals reports positive phase 4 trial results
ANI Pharmaceuticals (NASDAQ: ANIP) announced positive results from its Phase 4 SYNCHRONICITY clinical trial for fluocinolone acetonide intravitreal implant, which met both co-primary endpoints for treating chronic non-infectious uveitis. The trial demonstrated significant improve
- Tone
- Positive 76/100
- Event
- Earnings
- Published
- 13 Jul 2026 11:10
- Source
- Investing.com
grafa.com
Direct company coverage
ANI Pharmaceuticals reports positive uveitis trial results
ANI Pharmaceuticals (NASDAQ:ANIP) announced positive six-month results from its Phase 4 SYNCHRONICITY trial for a fluocinolone acetonide intravitreal implant used to treat chronic non-infectious uveitis. The trial met both primary endpoints, demonstrating significant improvements
- Tone
- Positive 77/100
- Event
- Earnings
- Published
- 13 Jul 2026 11:06
- Source
- grafa.com
TradingView
Direct company coverage
Enterprise value to EBIT forward of ANI Pharmaceuticals, Inc. – BX:BSFA
This article focuses on the enterprise value to EBIT forward ratio for ANI Pharmaceuticals, Inc. (BX:BSFA). It appears to be a financial data point from TradingView, indicating a specific financial metric for the company. The content itself seems to be a page snippet from a finan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 01:10
- Source
- TradingView
Sahm
Direct company coverage
ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity?
ANI Pharmaceuticals has initiated a Class III recall of its hydrOXYzine Hydrochloride Oral Solution due to a foreign substance, causing a short-term dip in its stock price. Despite this, the company has shown strong long-term shareholder returns, and a widely followed valuation n
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 11 Jul 2026 13:40
- Source
- Sahm
Market source
Direct company coverage
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
Stephen Carey, CFO of ANI Pharmaceuticals, sold 2,850 shares of common stock worth $239,742 as part of a pre-scheduled Rule 10b5-1 plan. This sale represented a modest 1.6% reduction of his direct holdings and is not considered a signal of a negative outlook on the company. The c
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 09 Jul 2026 22:17
- Source
- Market source
TradingView
Direct company coverage
Enterprise value to revenue forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
This article focuses on the enterprise value to revenue forward metric for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company. The content itself seems to be a page header and n
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 20:17
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
This article provides financial information for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) focusing on its price to sales forward metric. It displays market data and general financial overview for the company. The content appears to be a snapshot from a financial data platform.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 01:40
- Source
- TradingView
Sahm
Direct company coverage
Is Stronger Free Cash Flow Signalling a Shift in ANI Pharmaceuticals' Capital Efficiency Story (ANIP)?
ANI Pharmaceuticals (ANIP) has demonstrated strong operational progress with 33.6% annual revenue growth and higher free cash flow margins, indicating improved efficiency. The company's recent raised 2026 revenue guidance and share repurchase authorization reflect management's co
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 23:41
- Source
- Sahm
Stock Titan
Direct company coverage
ANIP (ANIP) insider sales reported: Walsh sold 13,973 shares in May 2026
A Form 144 filing for ANI Pharmaceuticals (ANIP) reports that Patrick Walsh sold 13,973 shares in two transactions in May 2026, totaling over $1.1 million. The filing also indicates 4,336 restricted shares dated May 22, 2026, described as "Securities To Be Sold" from the issuer.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 19:39
- Source
- Stock Titan
Investing.com
Direct company coverage
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $284k in stock
Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals Inc., recently sold $284,918 worth of common stock after exercising stock options. This transaction occurred on July 2, 2026, under a pre-arranged trading plan. The company has shown strong financial performance, including a 31%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 11:40
- Source
- Investing.com
Investing.com Canada
Direct company coverage
Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com
This article reports on a Form 4 filing for ANI Pharmaceuticals Inc. (ANIP) for insider transactions that occurred on July 6th. The content is brief, primarily serving as an announcement for the filing, with no further details provided within the article itself. It includes stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 02:10
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
ANI Pharmaceuticals (ANIP) CFO sells 3,313 shares after option exercise
Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals (ANIP), exercised stock options for 3,313 shares and subsequently sold all 3,313 shares at $86 each on July 2, 2026. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted on March 6, 2026. After the sale, Car
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 02:10
- Source
- Stock Titan
TradingView
Direct company coverage
Price to earnings forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
This page from TradingView provides financial information for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), specifically focusing on its forward price-to-earnings ratio. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC fil
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 23:10
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
This article provides access to the "Price to book forward" financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on TradingView. It highlights that the market was closed with no trades at the time of viewing. The page is part of TradingView's comprehensive financial data a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 00:40
- Source
- TradingView
Investing.com
Direct company coverage
ANI Pharmaceuticals set to report earnings amid estimate cuts
ANI Pharmaceuticals is scheduled to release its first-quarter earnings, with analysts expecting a sequential decline in EPS and revenue despite a year-over-year increase in revenue. Despite recent estimate cuts and a stock price below its 52-week high, analysts remain largely bul
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 11:10
- Source
- Investing.com
TradingView
Direct company coverage
Enterprise value to EBITDA forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
This article provides financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of publication, and there were no trades. The content is primarily a data point
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 10:10
- Source
- TradingView
GuruFocus
Direct company coverage
Insider Sell: Stephen Carey Sells Shares of ANI Pharmaceuticals Inc (ANIP)
Stephen Carey, Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals Inc (ANIP), sold 2,850 shares on June 29, 2026, reducing his holdings to 177,543 shares. Over the past year, Carey has sold 63,474 shares, contributing to a total of 50 insider sells and no insi
- Tone
- Negative 28/100
- Event
- Market update
- Published
- 01 Jul 2026 08:39
- Source
- GuruFocus
Stock Titan
Direct company coverage
ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan
ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, sold 2,850 shares of common stock at a weighted average price of $84.12 per share, totaling approximately $240,000. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following t
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 30 Jun 2026 20:15
- Source
- Stock Titan
TradingView
Direct company coverage
ANI Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ANIP)
This article provides an overview of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) stock, including its current price, performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings, revenue, net income, and market capitalization, along with freq
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 27 Jun 2026 06:30
- Source
- TradingView
Seeking Alpha
Direct company coverage
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple (NASDAQ:ANIP)
ANI Pharmaceuticals is presented as a speculative buy due to its transformational growth from Cortrophin Gel, a rare disease treatment. Management projects Cortrophin revenue to reach $540M-$575M by 2026, shifting the company's focus and potentially leading to a re-rating of its
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 26 Jun 2026 14:39
- Source
- Seeking Alpha